i-Lumen Scientific Private Investor Briefing - Virtual
Dear Investors,
Opus8 is hosting a virtual, invitation-only private investor briefing featuring i-Lumen Scientific, an ophthalmology company developing a non-invasive treatment designed to restore vision in patients with Dry Age-Related Macular Degeneration (Dry-AMD).
This session is hosted by Opus8 in collaboration with the New York Private Equity Forums (NYPEF).
Company Overview
i-Lumen is advancing a non-invasive, physician-delivered therapy designed to restore vision in Dry-AMD patients, with clinical data demonstrating meaningful improvement. Operating in a large, underserved market, the company is positioned for near-term value inflection through its pivotal trial and planned FDA pathway.
What Differentiates i-Lumen
• Demonstrated Clinical Results — Patients showed meaningful vision improvement with sustained outcomes
• Non-Invasive Approach — Physician-delivered therapy designed to restore, not just preserve, vision
• Large Market Opportunity — 200M+ patients globally, with significant unmet need
• Strategic Positioning — Strong acquisition precedent in ophthalmology, including recent $850M transaction
• Active Raise — Currently raising a $35M Series B, with $18M already committed
Event Details:
Date: Tuesday, April 14
Time: 11:30 AM EDT
Location: Online via Zoom
Please note that this meeting is for DIRECT and ACTIVE Accredited investors only. All RSVPs must be pre-registered on this site with the investor criteria filled out. All RSVPs are subject to review and approval. We will provide a confirmation email and a calendar invitation after you register.
Request investor materials by contacting Avery North at [email protected].
Thanks much and all the best,
Tien Wong
CEO
Opus8, Inc.